Foreword

The commitment to achieving nuclear security globally needs the efforts of both men and women, as diversity and gender equality bring benefits to all fields. However, women are underrepresented in nuclear security, as well as in the nuclear field in general, so it is important to understand and tackle the barriers that women can face to joining and thriving in the field, and I believe this special issue of the International Journal of Nuclear Security (IJNS) on Women in Nuclear Security will help in this regard

Immunogenetic markers in connection with the radiation effect on the man's organism

The object of investigation: lymphocytes of the peripheral blood. 367 men to be subjected to the different radiation effects and 200 men, the checking group, have been examined. The purpose of the work: to determine the possible immunogenetic markers HIA of the man's organism individual radiosensitivity system which would allow to evaluate the degree of risk with the action of the radiation factor for the persons possessing the different HIA rhenotypes. The immunogenetic markers of the man's organism radiosensitivity have been revealed in the system of antigenes of the main complex of the histocompatibility. Offered has been the determination of the risk of the pathological reactions arising with the radiation effect on the man's organism with the aid of the revealed HIA markers. It is possible to use the HIA markers when planning the protecting measures in the Byelorussia under the conditions existing after the Chernobyl AES emergencyAvailable from VNTIC / VNTIC - Scientific & Technical Information Centre of RussiaSIGLERURussian Federatio

Hematopoietic Recovery using Multi-Cytokine Therapy in 8 Patients Presenting Radiation-Induced Myelosuppression after Radiological Accidents

International audienceTreatment of accidental radiation-induced myelosuppressionis primarily based on supportive care and requiresspecific treatment based on hematopoietic growth factorsinjection or hematopoietic cell transplantation for the mostsevere cases. The cytokines used consisted of pegylatederythropoietin (darbepoetin alfa) 500 IU once per week,pegylated G-CSF (pegfilgrastim) 6 mg 3 2 once, stem cellfactor 20 lg.kg–1 for five days, and romiplostim (TPO analog)10 lg.kg1 once per week, with different combinationsdepending on the accidents. As the stem cell factor did nothave regulatory approval for clinical use in France, theFrench regulatory authorities (ANSM, formerly, AFSSAPS)approved their compassionate use as an investigational drug‘‘on a case-by-case basis’’. According to the evolution andclinical characteristics, each patient’s treatment was adoptedon an individual basis. Daily blood count allows initiating GCSFand SCF delivery when granulocyte ,1,000/mm3, TPOdelivery when platelets ,50,000/mm3, and EPO when Hb,80g/L. The length of each treatment was based on blood cellrecovery criteria. The concept of ‘‘stimulation strategy’’ islinked to each patient’s residual hematopoiesis, which variesamong them, depending on the radiation exposure’s characteristicsand heterogeneity. This paper reports the medicalmanagement of 8 overexposed patients to ionizing radiation.The recovery of bone marrow function after myelosuppressionwas accelerated using growth factors, optimized bymultiple-line combinations. Particularly in the event ofprolonged exposure to ionizing radiation in dose ranges inducing severe myelosuppression (in the order of 5 to 8 Gy),with no indication of hematopoietic stem cell transplantation